CHLORMERODRIN HG 197
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CHLORMERODRIN HG 197 (CHLORMERODRIN HG 197).
Radioactive mercury isotope that emits gamma rays; distributes in renal parenchyma, allowing scintigraphic imaging of kidneys. The mercury moiety binds to sulfhydryl groups in renal tubules, concentrating in functioning renal tissue.
| Metabolism | Not metabolized; excreted primarily via urine with significant reabsorption in renal tubules. Physical decay via electron capture to gold-197 with half-life of 64.1 hours. |
| Excretion | Renal: >90% of absorbed dose excreted in urine within 24 hours; biliary/fecal: <5%. |
| Half-life | Terminal elimination half-life approximately 3 days (72 hours) in patients with normal renal function; prolonged in renal impairment. |
| Protein binding | Approximately 20% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | 0.5-1.0 L/kg; distributes mainly into extracellular fluid and kidneys, with minimal intracellular penetration. |
| Bioavailability | Intravenous: 100%; no oral formulation. |
| Onset of Action | Intravenous: peak renal uptake within 1-2 hours; renal scan imaging optimal at 1-2 hours post-injection. |
| Duration of Action | Clinical visualization for renal imaging persists for 24-48 hours due to slow clearance; effective half-life for imaging is approximately 1-3 days. |
Chlormerodrin Hg 197 is administered intravenously as a single dose of 10 µCi (0.37 MBq) for renal imaging. The typical adult dose is 10-30 µCi (0.37-1.11 MBq) IV.
| Dosage form | INJECTABLE |
| Renal impairment | No specific GFR-based dose modifications are established. Use with caution in severe renal impairment due to potential increased radiation exposure and delayed excretion. |
| Liver impairment | No specific Child-Pugh based dose modifications are established. Hepatic impairment is unlikely to significantly alter pharmacokinetics as the drug is primarily renally excreted. |
| Pediatric use | Pediatric dose is calculated based on body surface area: adult dose × (child BSA / 1.73 m²). Typical minimum dose is 1 µCi (0.037 MBq). |
| Geriatric use | No specific dose adjustment is recommended for elderly patients. However, consider renal function and overall clinical status due to potential age-related decline in renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CHLORMERODRIN HG 197 (CHLORMERODRIN HG 197).
| Breastfeeding | Excreted in human breast milk. M/P ratio not established. Interrupt breastfeeding for at least 2 weeks after administration to minimize infant radiation exposure. Consider pumping and discarding milk during this period. |
| Teratogenic Risk | Chlormerodrin Hg 197 is a radiopharmaceutical containing radioactive mercury. Pregnancy category X: contraindicated in pregnant women due to radiation exposure. Risk of fetal harm, including growth retardation, malformations, and carcinogenesis, increases with radiation dose. Use alternative diagnostic methods during pregnancy. If administered inadvertently, assess fetal radiation dose and consider counseling. |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to mercury compounds","Pregnancy (unless benefit outweighs risk)","Lactation (discontinue nursing)"]
| Precautions | ["Radiation exposure risk to patients and healthcare workers; use only when diagnostic benefit outweighs risk.","Reduce dose in patients with severely impaired renal function due to prolonged retention.","Contraindicated in pregnancy unless essential; avoid breastfeeding after administration."] |
| Food/Dietary | No specific food interactions. Maintain adequate hydration as above. Caffeine and alcohol may affect renal function; avoid excessive intake before the procedure. |
Loading safety data…
| Fetal Monitoring | Monitor maternal radiation exposure dosimetry. For inadvertent administration during pregnancy, involve radiation safety officer and fetal dosimetry. Assess fetal radiation dose and provide appropriate counseling. No specific fetal monitoring otherwise. |
| Fertility Effects | Radiation exposure may cause temporary or permanent effects on gonadal function, potentially impairing fertility. Advise patients to avoid conception for at least 2 weeks post-administration. Consider alternative imaging in patients planning pregnancy. |
| Clinical Pearls |
| CHLORMERODRIN HG 197, a radiopharmaceutical for renal imaging, has a short half-life (approximately 2.7 days). Ensure adequate patient hydration before and after administration to reduce radiation exposure to the bladder. False positives in renal scans may occur with acute tubular necrosis or severe renal impairment. Contraindicated in pregnancy. Use sterile technique for injection. |
| Patient Advice | This medication is a radioactive diagnostic agent used for kidney imaging. · Drink plenty of fluids before and after the procedure to help clear the radioactive material from your body. · Notify your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding. · Avoid close contact with pregnant women and young children for a specified period after the injection (usually 24 hours). · Inform your doctor of any allergies or kidney problems. |